Accelerating Growth Amidst Global Headwinds: A Strong Q2 Performance from
The second quarter financial results conference call forprovided a comprehensive overview of the company's performance amidst significant headwinds in China and a softer respiratory environment. Despite these challenges, the underlying strength of the business remains evident, with total revenue increasing by 2% compared to the same period last year.
In fact, excluding China, revenue grew by a substantial 6%, reflecting broad-based strength across core franchises and regions. The company's Labs revenue outside of China witnessed a notable growth of 9%, while immunohematology revenue outside of China increased by 5%. TRIAGE also expanded by an impressive 9% during the quarter.
Geographically,'s performance was strong and broad-based, with North America growing by 6%. The region saw significant contributions from labs and the company's TRIAGE point of care business. Japan and India drove a remarkable growth of 10% in JPAC revenue, while Latin America grew at an impressive 8%, with notable strength in Brazil and Central America.
The adjusted EBITDA for the quarter increased by 21% to $129 million, representing a 310 basis point expansion of the EBITDA margin to 20% of revenue. This impressive margin expansion during what is typically considered the company's seasonally weakest quarter of the year underscores the effectiveness of its operational improvement initiatives.
One such initiative includes driving better productivity throughout the organization and exercising disciplined expense management, while focusing resources on the highest return opportunities. The company continues to invest in innovation and growth opportunities that will strengthen its competitive position and expand its addressable markets over time.
A significant example of this commitment is the commercialization of the LEX point of care molecular platform, now rebranded as NULEXA. Since completing the acquisition of LEX in April,has made substantial progress in advancing manufacturing scale-up, supply chain readiness, and commercial launch capabilities.
The early customer engagement with NULEXA has been very encouraging, and the company believes it addresses an important need in the market by combining molecular accuracy and rapid turnaround time with a simple, efficient workflow at the point of care. Importantly, NULEXA represents more than just a single product launch; it provides a scalable platform for future menu expansion and allowsto leverage its established commercial infrastructure, broad customer relationships, and deep expertise in point of care diagnostics.
This strategic move not only expands the company's capabilities but also demonstrates its ability to adapt and innovate in response to evolving market needs. The progress made byduring the second quarter is a testament to its resilience and commitment to delivering long-term value for its shareholders.
